Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers
Pharmacokinetic Properties of Fondaparinux Sodium in Morbidly Obese Volunteers
Sponsor: GlaxoSmithKline
Listed as NCT00436787, this PHASE2 trial focuses on Pulmonary Embolism and Venous Thrombosis and remains completed. Sponsored by GlaxoSmithKline, it has been updated 5 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Feb 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- University of Pittsburgh
For direct contact, visit the study record on ClinicalTrials.gov .